Kalypsys Raises $100 Million

Kalypsys Inc., a San Diego-based drug development company, has raised $100 million in Series C funding. Tavistock Life Sciences led the deal with an $89 million contribution, and was joined by fellow return backers Sprout Group, CMEA Ventures and KT Venture Group. The company now has raised around $172 million in VC funding since February 2002. www.kalypsys.com< ?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" />